- Home
- HFFG vs VTYX Comparison
HFFG vs VTYX Comparison
Compare HFFG & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFFG
- VTYX
- Stock Information
- Founded
- HFFG N/A
- VTYX 2018
- Country
- HFFG United States
- VTYX United States
- Employees
- HFFG N/A
- VTYX N/A
- Industry
- HFFG Food Distributors
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- HFFG Consumer Discretionary
- VTYX Health Care
- Exchange
- HFFG Nasdaq
- VTYX Nasdaq
- Market Cap
- HFFG 146.9M
- VTYX 154.9M
- IPO Year
- HFFG N/A
- VTYX 2021
- Fundamental
- Price
- HFFG $2.72
- VTYX $1.85
- Analyst Decision
- HFFG
- VTYX Buy
- Analyst Count
- HFFG 0
- VTYX 4
- Target Price
- HFFG N/A
- VTYX $11.33
- AVG Volume (30 Days)
- HFFG 43.6K
- VTYX 1.7M
- Earning Date
- HFFG 03-13-2025
- VTYX 02-25-2025
- Dividend Yield
- HFFG N/A
- VTYX N/A
- EPS Growth
- HFFG N/A
- VTYX N/A
- EPS
- HFFG N/A
- VTYX N/A
- Revenue
- HFFG $1,177,258,000.00
- VTYX N/A
- Revenue This Year
- HFFG $5.18
- VTYX N/A
- Revenue Next Year
- HFFG $2.73
- VTYX N/A
- P/E Ratio
- HFFG N/A
- VTYX N/A
- Revenue Growth
- HFFG 1.53
- VTYX N/A
- 52 Week Low
- HFFG $2.46
- VTYX $1.67
- 52 Week High
- HFFG $4.73
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- HFFG 36.86
- VTYX 39.93
- Support Level
- HFFG $2.70
- VTYX $1.91
- Resistance Level
- HFFG $2.80
- VTYX $2.15
- Average True Range (ATR)
- HFFG 0.10
- VTYX 0.16
- MACD
- HFFG 0.02
- VTYX -0.02
- Stochastic Oscillator
- HFFG 20.29
- VTYX 11.54
About HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The Company's business consists of one operating segment; HF Group, which operates solely in the United States. The Company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.